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Background
Incidence and risk factors of HIV-associated non-Hodgkin
lymphoma (NHL) in the era of combined anti-retroviral
therapy (cART) have not been well defined. We analyzed
incidence and risk factors for HIV-related NHL in the era
of cART within the framework of a large European multi-
cohort collaborative study.
Methods
We analyzed the data of HIV-infected adult patients (over
16 years old) who were cART naïve at inclusion and
started cART after January 1, 1998. cART was defined as
regimen with at least three antiretroviral drugs. Patients
had to have at least one CD4 cell count measurement after
January 1, 1998, and before start of HAART or diagnosis
of NHL. Both patients developing Primary Brain Lym-
phoma and systemic NHL were included in the analysis.
Incidence rates were calculated based on the Poisson dis-
tribution; risk factors were estimated using crude and
adjusted Weibull models, with random effects to account
for heterogeneity between cohorts. Models with time var-
ying covariates were used to explore the effect of CD4 cells
counts and plasma HIV-RNA loads over time. The data-
base included a total of 67,659 patients. Seventeen per-
cent of patients (11,354) were excluded from the analysis
because they did not meet the inclusion criteria outlined
above.
Results
We included 56,305 patients from 22 cohort studies
across Europe. During 212,042 person-years of follow up,
583 patients developed NHL. The incidence in patients
not on cART was 519 (95% CI 448 to 602) per 100,000
person-years compared to 229 (95% CI 208 to 252) per
100,000 person-years in those on cART. The incidence of
Primary Brain Lymphoma was 56.7 (95% CI 36 to 89) per
100,000 person-years in patients not on CART and 24
(95% CI 18 to 33) per 100,000 person years in patients on
cART. The incidence of systemic Non-Hodgkin Lym-
phoma other than Primary Brain Lymphoma was 463
(95% CI 395 to 541) per 100,000 in patients not on cART
and 205 (95% CI 185 to 227) per 100,000 person years in
patients on cART. In cART naïve patients the risk for NHL
increased with age, high plasma HIV-RNA loads and
decreasing CD4 cell counts. In patients receiving cART risk
factors for developing NHL were low CD4 cell counts,
higher age, belonging to the transmission risk group men
having sex with men and previous diagnosis of Kaposi
Sarcoma.
Conclusion
Combined anti-retroviral therapy reduces the risk of
developing NHL. In the era of cART more advanced
immunodeficiency is the dominant risk factor for devel-
oping NHL both in patients receiving and not receiving
cART for treatment of HIV infection.
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